生物技术公司CytoDyn Inc.宣布,其针对三阴性乳腺癌的Leronlimab扩大可及性项目已完成首位患者的首次给药。这一进展标志着该实验性疗法在特定患者群体中的临床应用迈出关键一步。
生物技术公司CytoDyn Inc.宣布,其针对三阴性乳腺癌的Leronlimab扩大可及性项目已完成首位患者的首次给药。这一进展标志着该实验性疗法在特定患者群体中的临床应用迈出关键一步。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.